4487-05-2

Basic information

• Product Name: 1-Benzyl-4-(4-aminobutyl)piperazine
• Synonyms: 1-Benzyl-4-(4-aminobutyl)piperazine;1-(4-Amino-1-butyl)-4-benzyl-piperazine
• CAS NO: 4487-05-2
• Molecular Formula: C₁₅H₂₅N₃
• Molecular Weight: 247.38
• Mol File: 4487-05-2.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 368.5 °C at 760 mmHg
• Flash Point: 174 °C
• Appearance: /
• Density: 1.025 g/cm³
• CAS DataBase Reference: 1-Benzyl-4-(4-aminobutyl)piperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Benzyl-4-(4-aminobutyl)piperazine(4487-05-2)
• EPA Substance Registry System: 1-Benzyl-4-(4-aminobutyl)piperazine(4487-05-2)

Safety Data

• Hazardous Substances Data: 4487-05-2(Hazardous Substances Data)

Usage

General Description

1-Benzyl-4-(4-aminobutyl)piperazine, also known as BAP, is a chemical compound with the molecular formula C18H28N2. It belongs to the class of piperazine derivatives and is commonly used in pharmaceutical research as a potential antipsychotic agent. BAP has also been studied for its potential applications as a dopamine receptor agonist and has shown promising results in preclinical studies. The compound has a piperazine core structure with a benzyl group attached at one end and a 4-aminobutyl group at the other, making it a versatile molecule for various medicinal chemistry applications. Due to its potential therapeutic properties, BAP continues to be a subject of interest in the field of drug discovery and development.

Upstream product

• 2759-28-6 1-phenylmethylpiperazine 
• 4487-04-1 2-(4-(4-benzylpiperazin-1-yl)butyl)isoindoline-1,3-dione 

Downstream Products

• 120301-41-9 (E)-N-[4-(4-Benzyl-piperazin-1-yl)-butyl]-3-phenyl-acrylamide 
• 1351411-83-0 N-(4-(piperazin-1-yl)butyl)cyclohexanecarboxamide 
• 1351411-84-1 N-(4-(4-(6-nitropyridin-2-yl)piperazin-1-yl)butyl)cyclohexanecarboxamide 
• 1351411-82-9 N-(4-(4-benzylpiperazin-1-yl)butyl)cyclohexanecarboxamide 
• 1351411-85-2 N-(4-(4-benzylpiperazin-1-yl)butyl)adamantane-1-carboxamide 

Relevant articles and documents

Synthesis, biological evaluation and molecular docking study of novel piperidine and piperazine derivatives as multi-targeted agents to treat Alzheimer's disease

Development of Multi-Target Directed Ligands (MTDLs) has emerged as a promising approach for targeting complex etiology of Alzheimer's disease (AD). Following this approach, a new series of N′-(4-benzylpiperidin-/piperazin-/benzhydrylpiperazin-1-yl)alkylamine derivatives were designed, synthesized and biologically evaluated as inhibitors of cholinesterases (ChEs), amyloid-beta (Aβ) self aggregation and also for their radical scavenging activity. The in vitro studies showed that the majority of synthesized derivatives strongly inhibited acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) with IC50 values in the low-nanomolar range, and were clearly more potent than the reference compound donepezil in this regard. Among them, inhibitors 5h and 5k, strongly inhibited AChE, with IC50 value of 6.83 nM and 2.13 nM, respectively, and particularly, compound 5k was found to be highly selective for AChE (～38-fold). Moreover, both kinetic analysis of AChE inhibition and the docking study suggested that 5k binds simultaneously to catalytic active site and peripheral anionic site of AChE. Besides, these compounds also exhibited greater ability to inhibit self-induced Aβ1-42 aggregation at 25 μM with percentage inhibition from ～54% to 89% and specially compound 5k provided highest inhibition (88.81%). Also, the derivatives containing methoxy and hydroxy groups showed potent oxygen radical absorbance capacity (ORAC) ranging from 2.2- to 4.4-fold of the Trolox value. Furthermore, results of ADMET studies suggested that all compounds exhibited appropriate drug like properties. Taken together, these results suggest that 5k might be a promising lead compound for further AD drug development.